公开(公告)号：US10302657B2

公开(公告)日：2019-05-28

申请号：US14264377

申请日：2014-04-29

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Barbara Denk ,  Martin Hund

IPC: G01N33/574 ,  G01N33/68 ,  G01N33/74

Abstract: Diagnostic methods and tools relating to diagnosing whether a pregnant subject is at risk for developing preeclampsia and/or early-onset preeclampsia within a short period of time. The methods include determining the amounts of the biomarkers sFlt-1 or Endoglin and PIGF in a first and a second sample of said subject, said first sample being obtained prior to said second sample; calculating a first ratio from the amounts of sFlt-1 or Endoglin and PIGF determined in the first sample, and a second ratio from the amounts of sFlt-1 or Endoglin and PIGF determined in the second sample; and comparing the value of the first and the second ratio, whereby a subject being at risk for developing preeclampsia within a short period of time is diagnosed if the value of the second ratio is increased compared to the value of the first ratio by a factor of at least about 3.

公开(公告)号：US20220128568A1

公开(公告)日：2022-04-28

申请号：US17463876

申请日：2021-09-01

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Barbara Denk ,  Martin Hund

IPC: G01N33/68 ,  C07K16/22 ,  G01N33/74

Abstract: Diagnostic methods and tools relating to diagnosing whether a pregnant subject is at risk for developing preeclampsia and/or early-onset preeclampsia within a short period of time. The methods include determining the amounts of the biomarkers sFlt-1 or Endoglin and PIGF in a first and a second sample of said subject, said first sample being obtained prior to said second sample; calculating a first ratio from the amounts of sFlt-1 or Endoglin and PIGF determined in the first sample, and a second ratio from the amounts of sFlt-1 or Endoglin and PIGF determined in the second sample; and comparing the value of the first and the second ratio, whereby a subject being at risk for developing preeclampsia within a short period of time is diagnosed if the value of the second ratio is increased compared to the value of the first ratio by a factor of at least about 3.

公开(公告)号：US20190227074A1

公开(公告)日：2019-07-25

申请号：US16373098

申请日：2019-04-02

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Barbara Denk ,  Martin Hund

IPC: G01N33/68 ,  G01N33/74

Abstract: Diagnostic methods and tools relating to diagnosing whether a pregnant subject is at risk for developing preeclampsia and/or early-onset preeclampsia within a short period of time. The methods include determining the amounts of the biomarkers sFlt-1 or Endoglin and PIGF in a first and a second sample of said subject, said first sample being obtained prior to said second sample; calculating a first ratio from the amounts of sFlt-1 or Endoglin and PIGF determined in the first sample, and a second ratio from the amounts of sFlt-1 or Endoglin and PIGF determined in the second sample; and comparing the value of the first and the second ratio, whereby a subject being at risk for developing preeclampsia within a short period of time is diagnosed if the value of the second ratio is increased compared to the value of the first ratio by a factor of at least about 3.

公开(公告)号：US20140234879A1

公开(公告)日：2014-08-21

申请号：US14264377

申请日：2014-04-29

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Barbara Denk ,  Martin Hund

IPC: G01N33/68 ,  G01N33/74

CPC classification number: G01N33/689 ,  G01N33/74 ,  G01N2800/368 ,  G01N2800/50

Abstract: Diagnostic methods and tools relating to diagnosing whether a pregnant subject is at risk for developing preeclampsia and/or early-onset preeclampsia within a short period of time. The methods include determining the amounts of the biomarkers sFlt-1 or Endoglin and PIGF in a first and a second sample of said subject, said first sample being obtained prior to said second sample; calculating a first ratio from the amounts of sFlt-1 or Endoglin and PIGF determined in the first sample, and a second ratio from the amounts of sFlt-1 or Endoglin and PIGF determined in the second sample; and comparing the value of the first and the second ratio, whereby a subject being at risk for developing preeclampsia within a short period of time is diagnosed if the value of the second ratio is increased compared to the value of the first ratio by a factor of at least about 3.

Abstract translation: 与诊断怀孕受试者是否处于在短时间内发展子痫前期和/或早发型先兆子痫的风险有关的诊断方法和工具。 所述方法包括测定所述受试者的第一和第二样品中生物标志物sFlt-1或Endoglin和PIGF的量，所述第一样品在所述第二样品之前获得; 从第一样品中测定的sFlt-1或Endoglin和PIGF的量计算第一比例，以及从第二样品中测定的sFlt-1或Endoglin和PIGF的量的第二比率; 并且比较第一和第二比率的值，由此如果第二比率的值比第一比率的值增加一个因子，则诊断在短时间内处于发展先兆子痫风险的对象 至少约3。